Skye Bioscience Inc’s recent filing unveils that its Director Schwab Andrew J. unloaded Company’s shares for reported $0.58 million on Aug 22 ’25. In the deal valued at $3.42 per share,170,449 shares were sold. As a result of this transaction, Schwab Andrew J. now holds 57,493 shares worth roughly $87389.36.
Then, Schwab Andrew J. sold 60,956 shares, generating $217,613 in total proceeds. Upon selling the shares at $3.57, the Director now owns 63,963 shares.
Before that, 5AM Partners VII, LLC sold 170,449 shares. Skye Bioscience Inc shares valued at $582,936 were divested by the 10% Owner at a price of $3.42 per share. As a result of the transaction, 5AM Partners VII, LLC now holds 57,493 shares, worth roughly $87389.36.
Craig Hallum downgraded its Skye Bioscience Inc [SKYE] rating to a Hold from a a Buy in a research note published recently. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who decreased its forecast for the stock in early October from “an Overweight” to “a Neutral”. Evercore ISI began covering SKYE with “an Outperform” recommendation on August 15, 2025. William Blair started covering the stock on February 28, 2025. It rated SKYE as “an Outperform”.
Price Performance Review of SKYE
On Tuesday, Skye Bioscience Inc [NASDAQ:SKYE] saw its stock jump 1.00% to $1.52. Over the last five days, the stock has lost -8.43%. Skye Bioscience Inc shares have fallen nearly -59.36% since the year began. Nevertheless, the stocks have fallen -46.29% over the past one year.
How much short interest is there in Skye Bioscience Inc?
A steep rise in short interest was recorded in Skye Bioscience Inc stocks on 2025-09-30, growing by 0.22 million shares to a total of 2.96 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-29 was 2.74 million shares. There was a rise of 7.4%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on September 30, 2024 when Scotiabank began covering the stock and recommended ‘”a Sector outperform”‘ rating along with a $20 price target.
